Approval · Notice of Compliance 18777 · 2016
DEXILANT: Notice of Compliance 18777
Issued December 16, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18777
- Date
- December 16, 2016
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the lalbelling of the safety information with respect to interaction with antiretroviral products
Products in this notice
Medicinal ingredients
- DEXLANSOPRAZOLE 30 MG per CAP
- DEXLANSOPRAZOLE 60 MG per CAP